Association Between MMR Status and Prognostic Pathological Factors in Endometrioid Endometrial Cancer-A Single-Center...

Area of Science:

• Gynecologic Oncology
• Cancer Biomarkers
• Molecular Pathology

Background:

• Endometrial cancer (EC) prognosis relies on clinical/pathological factors.
• MMR status (dMMR vs. pMMR) is key for immunotherapy prediction.
• Understanding dMMR/pMMR differences in prognostic factors is crucial.

Purpose of the Study:

• To compare the prevalence of adverse histopathological prognostic factors between dMMR and pMMR endometrioid endometrial carcinoma (EEC).

Main Methods:

• Retrospective analysis of 179 EEC patients (Jan 2023-Aug 2025).
• MMR status determined by immunohistochemistry.
• Clinicopathological variables (FIGO stage, grade, LVSI, ER/PR, P53, myometrial invasion) analyzed.
• Statistical analysis included Shapiro-Wilk, chi-square/Fisher's exact, Mann-Whitney, and logistic regression.

Main Results:

• dMMR tumors comprised 29.05% of cases.
• dMMR group showed significantly higher rates of FIGO stage III/IV disease (p=0.036) and lymphovascular space invasion (LVSI) (p=0.008).
• No significant differences in tumor grade, ER/PR positivity, or deep myometrial invasion were found.

Conclusions:

• dMMR endometrial cancer exhibits more adverse prognostic features, including advanced stage and LVSI.
• These findings support the potential efficacy of immunotherapy in dMMR EC patients.